Cartesian Therapeutics (RNAC) Total Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Total Liabilities data on file, last reported at $436.5 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $436.5 million, up 1.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $436.5 million (up 1.3% YoY), and the FY2025 annual result was $422.7 million, down 4.34% from the prior year.
• Total Liabilities grew to $436.5 million in Q1 2026 per RNAC's latest filing, from $422.7 million in the prior quarter.
• Over five years, Total Liabilities peaked at $454.6 million in Q3 2024 and troughed at $45.7 million in Q3 2023.
• A 5-year average of $286.9 million and a median of $408.5 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities slumped 54.19% in 2022, then surged 894.56% in 2024.
• A 5-year view of Total Liabilities shows it stood at $72.1 million in 2022, then soared by 517.11% to $444.7 million in 2023, then retreated by 0.64% to $441.8 million in 2024, then fell by 4.34% to $422.7 million in 2025, then rose by 3.28% to $436.5 million in 2026.
• Business Quant data shows RNAC's Total Liabilities at $436.5 million in Q1 2026, $422.7 million in Q4 2025, and $408.5 million in Q3 2025.